Legal Peptides, Explained

What Actually Happened at the FDA

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted on whether seven popular peptides should be added to the 503A Bulks List — the list that determines what compounding pharmacies are legally allowed to prepare for patients with a prescription.

This is not FDA drug approval. It's a separate, narrower pathway that lets licensed compounding pharmacies legally prepare these peptides for patients under a physician's prescription — without either the peptide being an FDA-approved drug or the current gray-market free-for-all continuing.

A "yes" vote does not make a peptide FDA-approved. It's a recommendation to add the substance to a list compounding pharmacies can legally draw from. The FDA still has to act on it through formal rulemaking.

Here's what most headlines skipped: this vote wasn't the start of legal access — it was the next step in a process already underway. Licensed physicians and compounding pharmacies had been legally prescribing and preparing these peptides all along. That was never illegal. What's been missing is FDA approval — and those are two different things.

Worth sitting with, no matter what year you're reading this: FDA approval isn't the same thing as safety. Plenty of fully-approved medications carry real side effects and real patient harm. What actually protects you is a licensed physician who knows your history, and a compounding pharmacy that tests what it makes.

How Each Peptide Landed

Six recommended for legal compounding. 

One held back over safety data gaps.

The Real Risk Isn't the Peptide

It's what's often still in the vial when nobody's watching.

Read It Straight From the Source

Four outlets covering the same vote — from different angles.

Notes the vote brings BPC-157 a step closer to being legally available with a prescription — but stresses that FDA staff scientists highlighted a lack of quality data on safety and effectiveness.

Frames the vote as a win for peptide advocates while noting the recommendation isn't binding — the FDA has gone against this committee's advice before, and still has to make the final call.

Direct about the distinction that matters most: these votes don't make peptides FDA-approved drugs. They recommend adding them to a list compounding pharmacies are allowed to prepare — a meaningfully different, and more limited, kind of approval.

Goes deeper into the FDA's own briefing materials — adverse event reports and testimony from physicians, compounding pharmacies, and public health advocates on both sides of the vote.

I've Done the Research So You Don't Have To

I've sat through the testimony, read the briefing documents, and watched this industry from the inside. Of everyone doing this, one U.S. company stood out to me as doing it the right way — willing to go to the line on transparency, licensed physician oversight, and the quality testing most others skip.

That company is EllieMD. Physician-reviewed. Prescription-based. Compounded in licensed U.S. pharmacies. Delivered to your door.

FDA Live Broadcast Replays

If you'd rather hear the discussion firsthand, here are the two YouTube links for the live FDA meeting broadcasts. Add your video URLs below so visitors can watch both sessions directly from the source.

Tip: once you have the final YouTube URLs, these buttons can be updated to link directly to each replay.